Coagulation Testing For New Oral Anticoagulants.

Atrial fibrillation is the most common and important cardiac rhythm disorder, which increases the risk of stroke and mortality. New oral anticoagulants are an alternative for vitamin K antagonists to prevent stroke in patients with non-valvular atrial fibrillation. New oral anticoagulants do not require routine monitoring of coagulation. However, the quantitative assessment of the anticoagulant effect drug levels may be needed in emergency situations, such as a serious bleeding or need for urgent surgery, or in patient with renal or hepatic insufficiency. In the paper we focus on the coagulation testing for new oral anticoagulants.